Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock (UNIRING-OBS SH)
Prospective Multicenter Observational Comparative Cohort Study of Actual UNIFUZOL® (Arginine Sodium Succinate) Versus Lactated Ringer's Use in Adults With Urinary- or Pulmonary-Source Sepsis During the Early Stabilization/Resolving Phase of Septic Shock and Documented Lower-Extremity Atherosclerotic Disease: Peripheral Perfusion, NIRS Vascular Reactivity, and Macro-Microhemodynamic Coherence
Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Alexey Kovalenko, Doc Biol Sci
- 電話番号:212 +78127108225
- メール:science@polysan.ru
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.
説明
Inclusion Criteria:
- Age 18 years or older.
- Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
- Urinary or pulmonary/respiratory suspected or confirmed infection source.
- Documented atherosclerotic disease of the lower-extremity arteries.
- Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
- PiCCO Plus already installed for clinical indications and technically usable.
- At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
- Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
- Thenar NIRS-VOT can be performed safely.
- Informed consent or another ethics-board-approved consent process is completed before study-specific procedures.
Exclusion Criteria:
- Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
- Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
- Clinically important fluid overload/pulmonary edema for which the treating physician considers additional fluid contraindicated; severe unstable ARDS.
- Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
- Expected survival less than 24 hours or limitation of intensive treatment.
- Pregnancy or breastfeeding.
- Participation in an interventional study expected to materially affect hemodynamics.
- Contraindication to any component of the physician-selected fluid.
- Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
- Core temperature below 34 degrees Celsius.
- Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
- Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CONTROL
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
UNIFUZOL® exposure cohort
Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
|
Lactated Ringer's exposure cohort
Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Capillary Refill Time at 6 Hours
時間枠:6 hours after start (window ±60 minutes)
|
Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Thenar NIRS Reoxygenation Slope at 6 Hours
時間枠:6 hours after start (window ±60 minutes)
|
Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable. |
6 hours after start (window ±60 minutes)
|
|
Sustained Macro-Microhemodynamic Coherent Response
時間枠:6 and 12 hours after start
|
Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory. |
6 and 12 hours after start
|
|
Change in Capillary Refill Time Over 24 Hours
時間枠:From start through 24 hours
|
Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models. |
From start through 24 hours
|
|
Change in ReOx
時間枠:From pre-infusion baseline through 24 hours
|
Serial ReOx from standardized NIRS-VOT. |
From pre-infusion baseline through 24 hours
|
|
Change in De-oxygenation slope
時間枠:From pre-infusion baseline through 24 hours
|
DeOx from standardized NIRS-VOT (%/min). |
From pre-infusion baseline through 24 hours
|
|
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
時間枠:From pre-infusion baseline through 24 hours
|
Tissue oxygenation variables (%) |
From pre-infusion baseline through 24 hours
|
協力者と研究者
スポンサー
スポンサー
捜査官
捜査官
- スタディチェア:K.M. Lebedinsky、North-Western State Medical University named after I.I.Mechnikov
- 主任研究者:I. S. Simutis、Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
- 主任研究者:A.Yu. Yakovlev、City Hospital No. 38 named after N.A. Semashko
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- UNIRING-OBS SHOCK
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。